Abbott Laboratories: Capitalizing on the Shift to Decentralized Diagnostics

Market analysis highlights Abbott's strong position in the fast-growing point-of-care and at-home endocrinology diagnostics sector, driven by trends in diabetes and thyroid testing.

A recent industry analysis highlights Abbott Laboratories as a key player within the expanding global market for endocrinology diagnostics. The strategic implications for the company are significant, particularly as testing moves away from traditional laboratory settings.

Published on March 10, 2026, the study from Worldwide Market Reports (WMR) evaluates the competitive environment for endocrinology testing through to 2033. Abbott is ranked among the notable market participants, alongside other major firms including Roche Diagnostics, Siemens Healthineers, and Thermo Fisher Scientific.

Market Dynamics and Abbott's Position

The primary growth driver identified in the sector is the move toward decentralized testing solutions. Abbott stands to gain substantial benefits in the point-of-care and at-home testing segments, which operate outside conventional hospital labs. This trend is fueled by demand in application areas such as diabetes management, thyroid diagnostics, and general hormone analysis.

For Abbott, the diabetes segment holds particular relevance. The company's established Diabetes Care division is already deeply focused on monitoring and diagnostic solutions. According to the WMR analysis, the increasing integration of digital health tools into diagnostic devices will be a central development factor between 2026 and 2033.

Therapeutic Advancements and Competitive Landscape

While Abbott concentrates on diagnostics, competition is intensifying in the related therapeutic field. New Phase 1 data for the drug candidate ABBV-295, developed by AbbVie, demonstrated weight loss of up to 10% over 13 weeks in non-obese participants. Rival Pfizer is also advancing candidates in the metabolic disease space. Although these developments alter the broader market environment, they do not pose a direct threat to Abbott's core business, which remains firmly anchored in diagnosis and monitoring.

Financial Performance and Outlook

Currently, Abbott's share price trades approximately 22% below its 52-week high, positioning it notably under its 200-day moving average. The market report alone is unlikely to close this gap. The critical factor will be the company's ability to convert its strong standing in the growing at-home and point-of-care testing markets into tangible revenue growth. The upcoming quarterly earnings reports may provide the first concrete indications of this translation.